Send Message
View as an RSS Feed
  • Finding A Fair Value For Gilead  [View article]
    I too believe you are right
    Jan 14, 2016. 08:57 PM | 1 Like Like |Link to Comment
  • Half-Million Dollar Income Portfolio - May Update  [View article]
    Consider GILD.
    May 17, 2015. 09:02 PM | 4 Likes Like |Link to Comment
  • Making The Plays In Your Own Retirement  [View article]
    Define partial position please.
    Feb 20, 2015. 04:21 PM | 1 Like Like |Link to Comment
  • Gilead Sciences: Ignore Recent Insider Selling  [View article]
    If you're worried about pricing pressure from competition, get out of the stock market completely. Every company has competition. GILD knows what the competitions drugs can do and price their solution accordingly. GILD offers tremendous upside opportunity with their new Harvoni one pill solution vs. what the competition can do. Don't fret, take advantage of this dip and load up.
    Oct 14, 2014. 06:51 PM | 1 Like Like |Link to Comment
  • A Re-Analysis Of Gilead After Q2 Results And The Early Idelalisib Approval  [View article]
    You are right about the Shorts! They did the same thing to Apple last year.
    Jul 24, 2014. 09:07 PM | Likes Like |Link to Comment
  • Cirrus Logic: Is The Pain Over For This Apple Supplier?  [View article]
    Spot on!
    Apr 5, 2013. 07:02 AM | Likes Like |Link to Comment
  • Apple: Already (Essentially) A Private Company  [View article]
    Finally an article that hits to the bone. Apple doesn't give a damn what the stock holders or analysts think. They will keep developing great products that we, customers, love. Thanks.
    Mar 5, 2013. 05:09 PM | 7 Likes Like |Link to Comment
  • 11 analysts have lowered their Apple (AAPL -0.4%) targets in recent weeks, Fortune observes. Many of them attributed their cuts (I, II) to reports of iPhone order reductions, but the recent drop in Apple shares is probably playing a role as well. Topeka's Brian White maintains the highest target ($1,111), and ACI Research's Ed Zabisky the lowest ($270). The average target is still at $740, 44% above current levels.  [View news story]
    By the time Fortune goes to press, the news is old!
    Dec 28, 2012. 01:45 PM | 2 Likes Like |Link to Comment
  • Putting Apple's (AAPL -1.4%) recent moves in perspective: the company entered 2012 with a P/E of 11.53 (not counting its cash balance), and is leaving with a P/E of 11.69. But shares are still up 25% YTD, thanks to the earnings growth seen over the interim. Earnings are expected to rise 17% in FY13 (ends in September), and revenue 22%.  [View news story]
    Thanks and totally agree with your comments on HEDGERS. They'll scare you to death only to turn around and make a profit on the upside. Just hang strong.
    Dec 27, 2012. 05:03 AM | Likes Like |Link to Comment
  • Apple (AAPL) is reiterated a Buy with $900 price target by Jefferies' Peter Misek, who sees the firm's gross margin issues being positively resolved in Q4. Misek has Q4 iPhone sales of 53M - about 5-7M above the Street - which could boost margins by 80 bp. Add that to Apple's typical 300 basis point lowball (36%), and Misek sees CQ4 GM at 40%. He raises his EPS estimate to $16 from $15.50 (Street consensus: $13.52). Shares +0.8% premarket.  [View news story]
    What about Foxconn's admission about tight supply for iPhone 5 and their ability to get this issue resolved in time for Q4 sales?
    Nov 8, 2012. 09:02 AM | Likes Like |Link to Comment